Erman Akkus: SUMMARIES OF 5 TOP-READ ARTICLES OF Journal of Clinical Oncology and JCO Precision Oncology in 2023!
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“SUMMARIES OF 5 TOP-READ ARTICLES OF Journal of Clinical Oncology and JCO Precision Oncology in 2023!
JCO
1. Advanced BRAF-mutant melanoma, first line dabra+trame or nivo+ipi?
-The 2-year OS is favoring nivo+ipi, 71.8% vs 51.5% (p=0.01)
2.Neoadjuvant or adjuvant chemo in locally advanced colon cancer?
-T3-4, N0-2, M0 -6-week oxa+fluo and 18 postop VS. 24 postop
-Residual or recurrent disease within 2 years favoring neoadjuvant arm, 16.9% vs. 21.5% , rate ratio, 0.72 , p= 0.03
3.Epcoritamab in relapsed or refractory CD20+ large B-cell lymphoma
-Overall response rate 63.1% and the complete response rate 38.9%
4.Tarlatamab in relapsed/refractory SCLC
-Any-grade treatment-related adverse events in 90.7% and grade b % 3 in 30.8% -Objective response rate 23.4%
5.Niraparib+abireteron vs placebo+abireteron in mCRPC
-Radiographic progression-free survival favoring niraparib in the BRCA1/2 subgroup (16.6 v 10.9 mo, HR: 0.53, P = .001) and in overall HRR+ cohort (16.5 vs 13.7 moHR, 0.73, P = .022)
JCO PO
1.Maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer
-Non–BRCA HRRm gene panels were not predictive of PFS benefit.
2.Cost-effectiveness of NGS ves single-gene testing (SgT) for genetic molecular subtypes and oncogenic markers in advanced NSCLC
-NGS is cost-effective over SgT
3.Economic impact and the potential life-years gained (LYG) attributed to NGS compared with single-gene testing (SGT) in metastatic NSCLC
-Clinically relevant gains in survival with non-negligible reduction in costs
4.Cell-Free DNA-Based Multi-cancer Detection Test in Individuals with Symptoms Suspicious for Cancers
-detected a cancer signal with high specificity and moderate sensitivity, especially in GI cancers -cancers not detected were less clinically aggressive
5.A cross-ancestry integrated risk score (caIRS) that combines a cross-ancestry polygenic risk score (caPRS) with a clinical estimator for breast cancer (BC) risk
-Adding a caPRS to the Tyrer-Cuzick model improves BC risk stratification for women of multiple ancestries.
By the way, happy new year!!”
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023